A study published in the October 2007 issue of The American Journal of Sports Medicine links the use of high-volume shoulder pain pumps to Postarthroscopic Glenohumeral Chondrolysis (PAGCL), a painful condition caused by the deterioration of hyaline cartilage around the shoulder area to the point that bone meets bone.

The study found that up to 63 percent of the patients who receive shoulder pain pumps are at risk of developing PAGCL. Due to this high risk of PAGCL, the study’s authors recommended that patients avoid using shoulder pain pumps, especially those that use bupivacaine with epinephrine, until their side effects are further studied.

Postarthroscopic Glenohumeral Chondrolysis Symptoms & Treatment

Postarthroscopic Glenohumeral Chondrolysis usually occurs between three and five months after arthroscopic shoulder surgery, but some patients have developed PAGCL symptoms up to twelve months after surgery. Researchers believe that PAGCL symptoms are delayed for a few months following the arthroscopy because the shoulder is protected and there is not much significant use of the shoulder joint post-surgery. After about three months, the patient typically becomes more physically active, resulting in the onset of pain and other symptoms caused by the shoulder pain pump cartilage loss.

Because PAGCL permanently destroys hyaline cartilage in the shoulder joint, shoulder pain pump recipients who develop PAGCL often suffer from a limited range of motion and constant pain. Other PAGCL symptoms include:

  • stiff shoulder
  • clicking shoulder
  • popping shoulder
  • grinding shoulder
  • shoulder weakness

Unfortunately, PAGCL treatments are only palliative, meaning they merely treat PAGCL symptoms and do not cure the condition. Pain medication and further surgery, including shoulder replacement surgery (glenohumeral arthroplasty) in some cases, are typically the only available PAGCL treatment options.

Pain Pumps | PAGCL Legal Help

AstraZeneca PLC which manufactures an anesthetic that doctors use in pain pumps and shoulder pain pump manufacturers which include Stryker Corp., I-Flow Corp., DePuy, Inc., DJO, Inc., and Breg, Inc., have allegedly long known about the risk of PAGCL and yet have continued to sell and market pain pumps for use in the shoulder joint. Our attorneys believe these companies should be held responsible for the injuries their dangerous products cause, and consequently, are currently taking cases from individuals nationwide who are pursuing shoulder pain pump lawsuits as a result of shoulder pain pump complications, including PAGCL.

Contact our shoulder pain pump lawyers today for a free and confidential case evaluation.

Published November 17, 2011 by